Polyphor Ltd.’s decision to halt recruitment for two late-stage trials of murepavadin owing to a higher than expected rate of kidney injury has seen the Swiss biotech's stock sink and raised doubts over the future for the potential first-in-class Pseudomonas aeruginosa-targeted antibiotic.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?